Business, energy, technology, markets and global industry news from Business News Today

CD47

PharmaDeviceNews CD47
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Representative image: ALX Oncology’s evorpacept update highlights how CD47-high biomarker data and HER2-positive metastatic breast cancer trial design could shape the next phase of oncology drug development.
Pharma & Biotech

Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study

ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.

Read More
Pharma & Biotech

What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies

Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.

Read More
Pharma & Biotech

Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard

Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.

Read More